[68ga]ga-nota-sna002
PeptideexperimentalImaging agent
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 18, 2022 (NCT05490264)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 68-gallium
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05989997 | Phase 1 | Nov 1, 2023 | Fudan University, SmartNuclide Biopharma |
| NCT05490264 | Early Phase 1 (Phase 1) | Oct 18, 2022 | SmartNuclide Biopharma, Soochow University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| SmartNuclide Biopharma | For profit | 2 | 2 | 1 | 2022 |
| Fudan University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Soochow University | Academic/Hospital | 1 | 0 | 1 | 2022 |
3 organizations
Page 1 / 1